PureTech Health Stock

PureTech Health ROE

Delisted·Jun 19, 2026

The Return on Equity (ROE) of PureTech Health (PRTC.L) as of Aug 5, 2026 is 12.90 %. In the previous year, Return on Equity (ROE) was -14.16 % — a change of -191.14% (higher).

ROE

12.90 %

YoY

-191.14%

Last updated:

In 2026, PureTech Health's return on equity (ROE) was 12.90 %, a -191.14% increase from the -14.16 % ROE in the previous year.

Access this data via the Eulerpool API

PureTech Health Stock analysis

What does PureTech Health do? PureTech Health is an innovative company specializing in the development of novel medical therapies and solutions. The company was founded in 2002 by Daphne Zohar and is headquartered in Boston, USA. PureTech Health is listed on the London Stock Exchange and has become one of the leading biotech companies in recent years. The company's business model is based on identifying medical needs and developing new products and therapies to meet those needs. It utilizes cutting-edge technologies to work quickly and effectively. Research and development are closely linked in an iterative process. PureTech Health's main focus is oncology, specifically developing immune-oncology therapies that target the patient's immune system to strengthen their body's defense against cancer cells. The company has also developed an innovative drug discovery system that combines nanotechnology and artificial intelligence. Another focus area for PureTech Health is gastroenterology. The company has developed a novel technology that selectively releases medical substances in the intestine, allowing targeted treatment of gastrointestinal diseases. PureTech Health has also developed a new method for diagnosing colorectal cancer based on the identification of bacteria in feces. In the field of neuropsychiatric disorders, the company has promising research results. It has developed a new technology that enables targeted manipulation of the central nervous system, allowing for the treatment of conditions such as depression, anxiety disorders, and ADHD. To this end, PureTech Health has developed a novel nasal spray that delivers the active ingredients directly to the brain. Biosensing is another area of focus for PureTech Health. The company has developed a novel technology that allows for the measurement of medical parameters such as blood sugar, cholesterol, and blood pressure. The sensors are available in the form of patches or other wearable devices and are easy and convenient to use. This technology is intended to help older people and those with chronic illnesses better monitor their health. Overall, PureTech Health is an innovative biotech company that is constantly seeking novel medical solutions. It operates in various areas and has promising products and therapies in the pipeline. With its close integration of research and development, PureTech Health is able to quickly and flexibly respond to market changes. With strong management and an experienced team, the company is well-positioned for further growth in the coming years. PureTech Health is one of the most popular companies on Eulerpool.

ROE Details

Decoding PureTech Health's Return on Equity (ROE)

PureTech Health's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing PureTech Health's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

PureTech Health's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in PureTech Health’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about PureTech Health stock

Return on Equity (ROE) of PureTech Health is 12.90 % in 2026.

Return on Equity (ROE) of PureTech Health changed from -14.16 % to 12.90 %, representing a -191.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) PureTech Health since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s PureTech Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — PureTech Health

All Key Metrics — PureTech Health